Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization for international execution of Study SP-03-B101. The move follows recent regulatory approvals supporting study expansion and marks the transition of the Sapu003 program from an Australia-based clinical effort toward a broader multinational development strategy, including planned expansion into Europe.
SP-03-B101 is an open-label Phase 1b dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors. The company said GCT has already completed key regulatory submissions ahead of schedule and initiated clinical operations, site activation and study management activities. Sapu003 is an intravenous formulation of everolimus developed using Sapu Nano’s Deciparticle(TM) platform, which is designed to improve drug delivery and provide more predictable systemic exposure than oral administration while supporting future global registrational studies. This expansion is significant because it potentially accelerates the development timeline for Sapu003, a drug that could offer improved treatment options for patients with mTOR-sensitive cancers by providing a more predictable and potentially safer intravenous delivery method compared to oral everolimus.
The appointment of GCT, a global CRO with expertise in multinational trials, suggests that Oncotelic is preparing for a larger, more complex development program that could lead to global registration. The ability to conduct studies across multiple countries may also facilitate patient recruitment and diversity, which are important for regulatory approvals. For investors, this development signals that Oncotelic is actively advancing its pipeline and may be closer to generating value from its drug candidates. The company’s focus on high-unmet-need cancers and rare pediatric indications, as described in its mission, positions it in a niche market with potential for significant impact. However, the clinical-stage nature of the company means that regulatory and commercial risks remain high.
Oncotelic also benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio. These assets provide additional avenues for growth and diversification.
The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC. For more information about NetworkNewsWire and its services, please visit https://www.NetworkNewsWire.com.
